Focus on Patients and Value Creation
Our wholly owned pipeline is further enabled by a focus on biomarker-driven, patient-targeted approaches in oncology and autoimmune diseases. We are also poised to deliver a continuous stream of new clinical candidates and value-generating data in early clinical development.